Nexalis Therapeutics Limited (ASX:NX1), formerly InhaleRx Limited, is a Melbourne-based diversified clinical-stage biopharmaceutical company focused on advancing innovative drug candidates targeting neurological, oncological, and psychiatric conditions. The company rebranded to Nexalis Therapeutics and adopted the NX1 ASX ticker in February 2026, reflecting its evolution beyond inhaled therapies following the addition of the SRX-25 oral treatment program.

Recent Developments

Nexalis reported a net loss of $1,297,938 for the half-year ended 30 June 2026, compared with a loss of $854,332 in the prior corresponding period, primarily reflecting higher product development expenditure of $1,275,757 and director fees of $108,988. On the clinical side, the company successfully completed its Phase 1 trial for IRX-616a and is now progressing Phase 2 program design, with management evaluating a flexible and appropriately scaled development pathway. Some study-order activities were temporarily suspended, which will delay completion of the formal Clinical Study Report, though the company has access to sufficient data to continue Phase 2 planning. For IRX-211, a multicentre, randomised, double-blind study in opioid-tolerant cancer patients with breakthrough cancer pain targeting 156 participants, recruitment challenges are being addressed through direct engagement with additional clinical sites. The SRX-25 resistant depression oral program remains in the planning phase with a protocol drafted. Post-period, the company settled its $641,848 funding Facility liability, with 38.4 million shares held by the lender cancelled and 15 million Options issued.

Sector Context

Clinical-stage biopharmaceutical companies in pain management, neurology, and mental health continue to attract investor attention, particularly as the global opioid crisis drives Demand for non-addictive alternatives for breakthrough cancer pain. The global treatment-resistant depression market is also significant, with SRX-25 targeting an underserved population where existing therapies are inadequate. Clinical development is inherently capital-intensive and time-consuming, with late-stage trial costs substantially exceeding early-stage research.

Risk and Uncertainty

Nexalis is pre-revenue, with all three programs in development phases. The Phase 1 completion for IRX-616a is a positive milestone, but Phase 2 design and execution will require substantially more funding. IRX-211 recruitment difficulties are a material concern — poor patient recruitment is one of the most common reasons for clinical trial failure. The company's funding position requires ongoing management, and further Capital raisings are likely required.

Catalysts to Watch

The commencement and design announcement for the IRX-616a Phase 2 program is the most anticipated near-term catalyst. Resolution of IRX-211 recruitment challenges and any enrolment updates will also be significant. Any strategic Partnership or licensing discussion for any of the three programs would be a material positive, and progress on SRX-25 protocol finalisation represents a longer-term option for the portfolio.

Nexalis Therapeutics is at a critical juncture for each of its clinical programs, and the decisions made over the next 12 to 18 months — regarding Phase 2 design, recruitment strategy, and funding — will significantly shape the company's trajectory and investor interest.